News | November 09, 2025
Syngene International reports Q2 FY26 consolidated PAT at Rs. 67.1 Cr
Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025
Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025
A bio-analytical Remote Regulatory Assessment was also conducted from October 30 to November 7, 2025, and concluded with no observations
Orphan drug designation (ODD) by the USFDA for Desidustat, provides eligibility for a potential seven-year marketing exclusivity subject to the USFDA approval
Senores Pharmaceuticals (SPI) acquired 51% stake in Zoraya Pharmaceuticals
Oral semaglutide 25 mg was associated with the same weight loss efficacy in women with obesity regardless of menopausal stage, and patients reported improvements in physical function, respectively
Cupid has been allocated approximately 23.4 million units of female condoms per year
Exemestane is a key therapeutic used in the treatment of certain types of breast cancer in postmenopausal women
The study demonstrated strong clinical outcomes, with 94.8 per cent of subjects remaining free from major target limb amputation at one year
The expanded approval allows Kerendia to be prescribed to heart failure patients with a LVEF of 40% or more
From material selection to cooling tower management, every small decision affects long-term equipment reliability
Subscribe To Our Newsletter & Stay Updated
